



CLAIMS

1. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, isomer, tautomer, *N*-oxide, ester, isotope or protected form thereof:



wherein R^1 is selected from hydrogen and C_{1-4} alkyl;

Ar^1 is selected from any one of the following ring systems:



wherein R^2 is present, and is one or more substituents each independently selected from halogen, cyano, hydroxyl, hydroxyl C_{1-4} alkyl, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkyloxy, $-\text{C}_{1-4}$ alkyl C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkoxy, $\text{NR}^{\text{4A}}\text{R}^{\text{4B}}$, NO_2 , -

$\text{CONR}^{4A}\text{R}^{4B}$, $-\text{C}_{1-4}\text{alkylNR}^{4A}\text{R}^{4B}$, $-\text{C}_{1-4}\text{alkoxyNR}^{4A}\text{R}^{4B}$, $\text{C}_{3-7}\text{-cycloalkyl}$, morpholinyl, $\text{C}_{2-4}\text{alkynyl}$ and $-\text{CO}_2\text{R}^4$ wherein

R^3 is hydrogen or $\text{C}_{1-4}\text{alkyl}$,













R^4 is hydrogen or $\text{C}_{1-4}\text{alkyl}$,

R^{4A} and R^{4B} are each independently selected from hydrogen, $\text{C}_{1-4}\text{alkyl}$, $-\text{C}_{1-4}\text{alkylC}_{1-4}\text{alkoxy}$, and COR^4 , or

R^{4A} and R^{4B} , together with the nitrogen atom to which they are attached, join together to form a cyclic amino group, wherein the cyclic amino group is optionally substituted with oxo;

Ar^2 is a ring system selected from Groups (i), and (ii), wherein:

Group (i) is a 5-membered heteroaryl ring system selected from any one of (IIa) to (IIm):



wherein X^6 , X^7 , X^8 , and X^9 are each independently selected from O, S, and NH, and

R^5 is one or more optional substituents each independently selected from halogen, cyano, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-C_{1-4}$ alkyl C_{1-4} alkoxy, $-CO_2R^6$, and $-L-Q$ wherein:

L is a linker group selected from a direct bond, C_{1-3} alkylene and $-CO-$; and

Q is a group selected from $NR^{5A}R^{5B}$, C_3 cycloalkyl and 4-7 membered heterocyclyl, wherein the 4-7 membered heterocyclyl ring is optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy and CO_2R^6 ;

R^{5A} and R^{5B} are each independently selected from hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, COR^7 , $-C_{1-4}$ alkyl- NR^8R^9 , $-C_{1-4}$ alkyl C_{1-4} alkoxy, phenyl and 5 or 6-membered heteroaryl wherein the phenyl or 5 or 6-membered heteroaryl rings are optionally substituted with one or more substituents selected from halogen and C_{1-4} alkyl; or


R^{5A} and R^{5B} , together with the nitrogen atom to which they are attached, join together to form a cyclic amino group, which cyclic amino group is optionally substituted with one or more groups selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, and CO_2R^6 ,

R^6 is hydrogen, C_{1-4} alkyl or an alkali metal;

R^7 is C_{1-4} alkyl

R^8 and R^9 are each independently selected from hydrogen and C_{1-4} alkyl;

Group (ii) is a 5,6-fused bicyclic heteroaryl ring system having the formula (III):




wherein Y^2 is selected from O and NR^{5C} ;

R^{5C} is hydrogen or C_{1-4} alkyl,


X^{10} , X^{11} , X^{12} , and X^{13} are each independently selected from N and CH;


R^{10} is one or more optional substituents each independently selected from halogen, cyano, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, and $-CO_2R^4$;

PROVIDED THAT the compound of formula (I) is other than:




2. A compound according to claim 1 wherein R^1 is hydrogen.
3. A compound according to claim 1 or claim 2 wherein Ar^2 is selected from Group (i).
4. A compound according to any one of claims 1 to 3 wherein Ar^1 is selected from any one of the following ring systems:






and preferably, R^2 is independently selected from any one of fluoro, chloro, methyl, ethyl, iso-propyl, cyclopropyl, methoxy, trifluoromethyl, trifluoromethoxy ($-\text{OCF}_3$), $-\text{NR}^{4A}\text{R}^{4B}$, CO_2H , and CO_2CH_3 .

5. A compound according to any one of claims 1 to 3 wherein Ar^1 is selected from any one of the following ring systems:







;


and preferably, R^2 is independently selected from any one of fluoro, chloro, methyl, ethyl, iso-propyl, cyclopropyl, methoxy, trifluoromethyl, trifluoromethoxy ($-\text{OCF}_3$), $-\text{NR}^{4A}\text{R}^{4B}$, CO_2H , and CO_2CH_3 .

6. A compound according to any one of claims 1 to 4 wherein Ar^1 is independently selected from any one of the following ring systems:






7. A compound according to any one of claims 1 to 6 wherein Ar^2 is selected from any one of the following ring systems:



wherein R^5 is one or more optional substituents as set out in claim 1; and preferably wherein Ar^2 is selected from any one of the following ring systems:



wherein R^5 is a substituent as set out in claim 1.


8. A compound according to any one of claims 1 to 7 wherein R^5 is independently selected from any one of fluoro, chloro, methyl, isopropyl, tert-butyl, trifluoromethyl, cyclopropyl, CO_2Et , $-\text{NR}^{5A}\text{R}^{5B}$, $-\text{CONR}^{5A}\text{R}^{5B}$, $-\text{CH}_2\text{NR}^{5A}\text{R}^{5B}$, and a ring system selected from pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, any of which rings is optionally substituted with one or more groups selected from fluoro, chloro, methyl, methoxy, cyano, and CO_2^tBu ;

wherein R^{5A} and R^{5B} are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, $-\text{COCH}_3$, $-\text{CH}_2\text{CH}_2\text{N}(\text{CH}_3)_2$, $-\text{CH}_2\text{CH}_2\text{OCH}_3$, phenyl, and pyridyl, either of which phenyl, and pyridyl rings is optionally substituted with one or more groups selected from fluoro, chloro, and methyl; or


R^{5A} and R^{5B} which together with the nitrogen atom to which they are attached form a cyclic amino group selected from pyrrolidinyl, morpholinyl, piperidinyl, piperazinyl, any of which rings is optionally substituted with one or more groups selected from fluoro, methyl, methoxy, cyano, and CO_2^tBu ; and preferably wherein R^5 is independently selected from any one of fluoro, chloro, methyl, isopropyl, tert-butyl, trifluoromethyl, cyclopropyl, CO_2Et , $-\text{NR}^{5A}\text{R}^{5B}$, $-\text{CONR}^{5A}\text{R}^{5B}$, $-\text{CH}_2\text{NR}^{5A}\text{R}^{5B}$, and a ring

system selected from pyrrolidinyl, morpholinyl, piperidinyl and piperazinyl, any of which rings is optionally substituted with one or more groups selected from fluoro, chloro, methyl, methoxy, cyano, and CO_2^tBu ; wherein $\text{R}^{5\text{A}}$ and $\text{R}^{5\text{B}}$ are as defined in claim 8; and more preferably wherein R^5 is independently selected from any one of methyl, isopropyl, tert-butyl, cyclopropyl, $-\text{CONR}^{5\text{A}}\text{R}^{5\text{B}}$ and $-\text{CH}_2\text{NR}^{5\text{A}}\text{R}^{5\text{B}}$; and most preferably wherein R^5 is absent.


9. A compound according to any one of claims 1 to 6, wherein Ar^2 is selected from Group (i), R^1 is H and Ar^1 is selected from the following groups:




wherein R^2 is as defined in claim 1; and preferably wherein Ar^2 is selected from Group (i), R^1 is H and Ar^1 is selected from the following groups:




and more preferably wherein Ar^1 is selected from one of the following groups:







R^1 is H and Ar^2 is selected from any one of the following groups:




wherein R^2 and R^5 are as defined in claim 1.

10. A compound according to claim 9, wherein Ar^1 is selected from any one of the following groups:







R^1 is H and Ar^2 is selected from any one of the following groups:




wherein R^5 is as defined in claim 1; and preferably wherein Ar^1 is selected from any one of the following groups:







R¹ is H and Ar² is selected from any of the following groups:



wherein R^5 is as defined in claim 1; and more preferably wherein Ar^1 is selected from any one of the following groups:




R^1 is H and Ar^2 is the following group:




wherein R^5 is as defined in claim 1.


11. A compound according to claim 9 or claim 10, wherein Ar^1 is selected from any one of the following groups:




R^1 is H and Ar^2 is the following group:




wherein R^5 is C_{1-4} alkyl such as methyl, isopropyl, tert-butyl, cyclopropyl, $-CONR^{5A}R^{5B}$ and $-CH_2NR^{5A}R^{5B}$; and preferably wherein Ar^1 is selected from any one of the following groups:





R^1 is H and Ar^2 is the following group:



12. A compound as claimed in any one of claims 1 to 11 which is one of the Examples and pharmaceutically acceptable salts thereof, such as:

N-Methyl-2-((5-(trifluoromethyl)benzo[d]oxazol-2-yl)amino)thiazole-4-carboxamide,

N-(Thiazol-2-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,

N-(Isoxazol-3-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,

N-(1,3,4-Thiadiazol-2-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,

N-(5-Methyl-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,

N-(5-(Piperidin-1-yl)thiazol-2-yl)-6-(trifluoromethyl)benzo[d]oxazol-2-amine,

6-Chloro-N-(4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,

N-(5-Cyclopropyl-1,3,4-oxadiazol-2-yl)-6-(trifluoromethyl)oxazolo[4,5-c]pyridin-2-amine,


6-Fluoro-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,

N-(5-(Trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1,3,4-oxadiazol-2-amine,
 N-(5-(Pyrrolidin-1-ylmethyl)-1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,
 5-Methyl-N-(5-(trifluoromethyl)-1H-benzo[d]imidazol-2-yl)-1,3,4-thiadiazol-2-amine,
 2-((5-Chlorobenzo[d]oxazol-2-yl)amino)-N-(2-(dimethylamino)ethyl)thiazole-4-carboxamide,
 6-Chloro-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 N-(5-(Pyrrolidin-1-ylmethyl)-4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(4-(2-methoxyethyl)-5-methyl-4H-1,2,4-triazol-3-yl)-5-(trifluoromethyl)benzo[d]oxazol-2-amine,
 N-(Benzo[d]oxazol-2-yl)-6-(trifluoromethyl)oxazolo[4,5-c]pyridin-2-amine,
 6-Chloro-N-(5-methylisoxazol-3-yl)benzo[d]oxazol-2-amine,
 5-Chloro-N-(thiazol-4-yl)benzo[d]oxazol-2-amine,
 5-Fluoro-N-(1,3,4-oxadiazol-2-yl)-6-(trifluoromethoxy)benzo[d]oxazol-2-amine,
 6-Chloro-N-(5-cyclopropyl-1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-4-fluoro-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 2-((1,3,4-Oxadiazol-2-yl)amino)benzo[d]oxazol-6-ol,
 Methyl 2-((1,3,4-oxadiazol-2-yl)amino)benzo[d]oxazole-6-carboxylate,
 6-Bromo-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Cyclopropyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 (2-((1,3,4-Oxadiazol-2-yl)amino)benzo[d]oxazol-6-yl)methanol,
 4-((6-chlorobenzo[d]oxazol-2-yl)amino)oxazole-2-carboxylic acid,
 N-(1,3,4-oxadiazol-2-yl)-6-(pyrrolidin-1-yl)benzo[d]oxazol-2-amine,
 N-(1,3,4-Oxadiazol-2-yl)-6-(piperidin-1-yl)benzo[d]oxazol-2-amine,
 6-Morpholino-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Nitro-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 5-Chloro-6-methyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-5-methyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-4-methyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 5-Chloro-6-methoxy-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 5-Chloro-N-(1,3,4-oxadiazol-2-yl)-6-(trifluoromethoxy)benzo[d]oxazol-2-amine,
 2-((1,3,4-oxadiazol-2-yl)amino)benzo[d]oxazole-6-carboxylic acid,
 6-(2-methoxyethoxy)-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,

6-Chloro-N-(5-ethynyl-1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 N²-(1,3,4-oxadiazol-2-yl)benzo[d]oxazole-2,6-diamine,
 6-Isopropoxy-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 5-Fluoro-6-methyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(5-(pyrrolidin-1-yl)-1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(5-(tetrahydrofuran-3-yl)-1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 5-((6-Chlorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carboxamide,
 5-((6-Fluorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carboxamide,
 5-((5-Fluorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carboxamide,
 6-Fluoro-5-methyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-5-methoxy-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(1,3,4-oxadiazole-2-yl)-5-(trifluoromethoxy)benzo[d]oxazol-2-amine,
 5-Fluoro-6-methoxy-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Fluoro-N-(1,3,4-oxadiazol-2-yl)-5-(trifluoromethoxy)benzo[d]oxazol-2-amine,
 6-Methoxy-5-methyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Fluoro-5-methoxy-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 N-(1,3,4-Oxadiazol-2-yl)-6-(trifluoromethoxy)benzo[d]oxazol-2-amine,
 6-Isopropyl-N-(1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 1-(2-((1,3,4-oxadiazol-2-yl)amino)benzo[d]oxazol-6-yl)pyrrolidin-2-one,
 6-Chloro-N-(5-(tetrahydrofuran-2-yl)-1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(5-isopropyl-1,3,4-oxadiazol-2-yl)benzo[d]oxazol-2-amine,
 N-(2-((1,3,4-Oxadiazol-2-yl)amino)benzo[d]oxazol-6-yl)-N-methylacetamide,
 Ethyl 5-((6-chlorobenzo[d]oxazol-2-yl)amino)-1,2,4-oxadiazole-3-carboxylate,
 5-((6-Chlorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carbonitrile,
 5-((6-Fluorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carbonitrile,
 5-((5-Fluorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carbonitrile,
 6-Chloro-N-(1,3,4-oxadiazole-2-yl)oxazolo[4,5-b]pyridine-2-amine,
 6-Chloro-N-(oxazol-4-yl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(isothiazol-3-yl)benzo[d]oxazol-2-amine,
 Sodium 5-((6-fluorobenzo[d]oxazol-2-yl)amino)-1,3,4-oxadiazole-2-carboxylate,
 5,6-Chloro-N-(1,2,4-oxadiazol-5-yl)benzo[d]oxazol-2-amine,
 6-Chloro-N-(isoxazol-4-yl)benzo[d]oxazol-2-amine,
 and pharmaceutically acceptable salts thereof.





13. A pharmaceutical composition comprising a compound according to any one of claims 1 to 12, together with a pharmaceutically acceptable excipient or carrier
14. A compound according to any one of claims 1 to 12 for use in the treatment of a bacterial infection and/or a disease caused by a bacterial infection; and preferably wherein the bacterial infection is caused by Gram-positive and/or Gram-negative bacteria.
15. Use of a compound according to any one of claims 1 to 12 in manufacture of a medicament for the treatment of a bacterial infection and/or a disease caused by a bacterial infection; and preferably wherein the bacterial infection is caused by Gram-positive and/or Gram-negative bacteria.
16. The use according to claim 15 wherein the bacterial infection is caused by a bacteria selected from *Moraxella catarrhalis*, *Bacillus thuringiensis*, *Acinetobacter junii*, *Escherichia coli*, *Helicobacter pylori*, *Borrelia burgdorferi*, *Legionella pneumophila*, *Mycobacterium* spp (including *M. tuberculosis*, *M. leprae*, *M. avium*, *M. intracellulare*, *M. kansasii* and *M. goodii*), *Staphylococcus aureus*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A Streptococcus), *Streptococcus agalactiae* (Group B Streptococcus), *Streptococcus viridans*, *Streptococcus faecalis*, *Streptococcus bovis*, any anaerobic species of the genus *Streptococcus*, *Streptococcus pneumoniae*, *Campylobacter* spp., *Enterococcus* spp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium* spp. (including *C. diphtheriae*), *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Clostridium difficile*, *Clostridium innocuum*, *Peptostreptococcus anaerobius*, *Bacteroides fragilis*, *Enterobacter aerogenes*, *Klebsiella* spp (including *K. pneumoniae*), *Pasturella multocida*, *Bacteroides* spp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenue*, *Leptospira* spp., *Rickettsia* spp. and *Actinomyces* spp. (including *A. israelii*), *Acinetobacter baumannii*, *Pseudomonas aeruginosa*, and *Staphylococcus epidermidis*; and preferably wherein the bacterial infection is caused by a bacterium selected from: *Staphylococcus aureus*, *Enterococcus faecalis*, *Enterococcus faecium* and the *Neisseria* genus; and more preferably wherein the disease is caused by a bacterium selected from the *Neisseria* genus; and most preferably wherein the bacterial infection is *Neisseria gonorrhoeae*.


17. A compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, isomer, tautomer, *N*-oxide, ester, isotope or protected form thereof for use in the treatment of infection with, or disease caused by a bacterium selected from *Moraxella catarrhalis*, *Acinetobacter junii*, *Helicobacter pylori*, *Borrelia burgdorferi*, *Legionella pneumophila*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A Streptococcus), *Streptococcus agalactiae* (Group B Streptococcus), *Streptococcus viridans*, *Streptococcus faecalis*, *Streptococcus bovis*, any anaerobic species of the genus *Streptococcus*, *Streptococcus pneumoniae*, *Campylobacter* spp., *Enterococcus* spp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium* spp. (including *C. diphtheriae*), *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Clostridium difficile*, *Clostridium innocuum*, *Peptostreptococcus anaerobius*, *Bacteroides fragilis*, *Enterobacter aerogenes*, *Klebsiella* spp (including *K. pneumoniae*), *Pasturella multocida*, *Bacteroides* spp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenuis*, *Leptospira* spp., *Rickettsia* spp. and *Actinomyces* spp. (including *A. israelii*), *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*:



wherein R^1 is selected from hydrogen and C_{1-4} alkyl;

Ar^1 is selected from any one of the following ring systems:





wherein R^2 is one or more optional substituents each independently selected from halogen, cyano, hydroxyl, hydroxyl C_{1-4} alkyl, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, halo C_{1-4} alkoxy, $-C_{1-4}$ alkyl C_{1-4} alkoxy, C_{1-4} alkoxy C_{1-4} alkoxy, $NR^{4A}R^{4B}$, NO_2 , $-CONR^{4A}R^{4B}$, $-C_{1-4}$ alkyl $NR^{4A}R^{4B}$, $-C_{1-4}$ alkoxy $NR^{4A}R^{4B}$, C_{3-7} cycloalkyl, morpholinyl, C_{2-4} alkynyl and $-CO_2R^4$ wherein

R^3 is hydrogen or C_{1-4} alkyl,


R^4 is hydrogen or C_{1-4} alkyl,

R^{4A} and R^{4B} are each independently selected from hydrogen, C_{1-4} alkyl, $-C_{1-4}$ alkyl C_{1-4} alkoxy, and COR^4 , or

R^{4A} and R^{4B} , together with the nitrogen atom to which they are attached, join together to form a cyclic amino group, wherein the cyclic amino group is optionally substituted with oxo;

Ar^2 is a ring system selected from Groups (i), and (ii), wherein:

Group (i) is a 5-membered heteroaryl ring system selected from any one of (IIa) to (IIm):



wherein X^6 , X^7 , X^8 , and X^9 are each independently selected from O, S, and NH, and

R^5 is one or more optional substituents each independently selected from halogen, cyano, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-C_{1-4}$ alkyl C_{1-4} alkoxy, $-CO_2R^6$, and $-L-Q$ wherein:

L is a linker group selected from a direct bond, C_{1-3} alkylene and $-CO-$; and

Q is a group selected from $NR^{5A}R^{5B}$, C_3 cycloalkyl and 4-7 membered heterocyclyl, wherein the 4-7 membered heterocyclyl ring is optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy and CO_2R^6 ;

R^{5A} and R^{5B} are each independently selected from hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, COR^7 , $-C_{1-4}$ alkyl- NR^8R^9 , $-C_{1-4}$ alkyl C_{1-4} alkoxy, phenyl and 5 or 6-membered heteroaryl wherein the phenyl or 5 or 6-membered heteroaryl rings are optionally substituted with one or more substituents selected from halogen and C_{1-4} alkyl; or


R^{5A} and R^{5B} , together with the nitrogen atom to which they are attached, join together to form a cyclic amino group, which cyclic amino group is optionally substituted with one or more groups selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, and CO_2R^6 ,

R^6 is hydrogen, C_{1-4} alkyl or an alkali metal;

R^7 is C_{1-4} alkyl

R^8 and R^9 are each independently selected from hydrogen and C_{1-4} alkyl;

Group (ii) is a 5,6-fused bicyclic heteroaryl ring system having the formula (III):




wherein Y^2 is selected from O and NR^{5C} ;

R^{5C} is hydrogen or C_{1-4} alkyl,

X^{10} , X^{11} , X^{12} , and X^{13} are each independently selected from N and CH;

R^{10} is one or more optional substituents each independently selected from halogen, cyano, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, and $-CO_2R^4$;


PROVIDED THAT the compound of formula (I) is other than:



and preferably wherein the compound of formula (I) is for use in the treatment of infection with, or disease caused by a bacterium selected from *Enterococcus faecalis*, *Enterococcus faecium* and the *Neisseria* genus; more preferably for use in the treatment of infection with, or disease caused by a bacterium selected from the *Neisseria* genus; and most preferably for use in the treatment of infection with, or disease caused by the bacterium *Neisseria gonorrhoeae*.


18. Use of a compound of formula (I), or a pharmaceutically acceptable salt, hydrate, solvate, isomer, tautomer, *N*-oxide, ester, isotope or protected form thereof in the manufacture of a medicament for the treatment of infection with, or disease caused by


a bacterium selected from *Moraxella catarrhalis*, *Acinetobacter junii*, *Helicobacter pylori*, *Borelia burgdorferi*, *Legionella pneumophila*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Listeria monocytogenes*, *Streptococcus pyogenes* (Group A Streptococcus), *Streptococcus agalactiae* (Group B Streptococcus), *Streptococcus viridans*, *Streptococcus faecalis*, *Streptococcus bovis*, any anaerobic species of the genus *Streptococcus*, *Streptococcus pneumoniae*, *Campylobacter* spp., *Enterococcus* spp., *Haemophilus influenzae*, *Bacillus anthracis*, *Corynebacterium* spp. (including *C. diphtheriae*), *Erysipelothrix rhusiopathiae*, *Clostridium perfringens*, *Clostridium tetani*, *Clostridium difficile*, *Clostridium innocuum*, *Peptostreptococcus anaerobius*, *Bacteroides fragilis*, *Enterobacter aerogenes*, *Klebsiella* spp (including *K. pneumoniae*), *Pasturella multocida*, *Bacteroides* spp., *Fusobacterium nucleatum*, *Streptobacillus moniliformis*, *Treponema pallidum*, *Treponema pertenuis*, *Leptospira* spp., *Rickettsia* spp. and *Actinomyces* spp. (including *A. israelii*), *Acinetobacter baumannii*, and *Pseudomonas aeruginosa*:



wherein R^1 is selected from hydrogen and C_{1-4} alkyl;

Ar^1 is selected from any one of the following ring systems:





wherein R² is one or more optional substituents each independently selected from halogen, cyano, hydroxyl, hydroxylC₁₋₄alkyl, C₁₋₄alkyl, haloC₁₋₄alkyl, C₁₋₄alkoxy, haloC₁₋₄alkoxy, -C₁₋₄alkylC₁₋₄alkoxy, C₁₋₄alkoxyC₁₋₄alkoxy, NR^{4A}R^{4B}, NO₂, -CONR^{4A}R^{4B}, -C₁₋₄alkylNR^{4A}R^{4B}, -C₁₋₄alkoxyNR^{4A}R^{4B}, C₃₋₇cycloalkyl, morpholinyl, C₂₋₄alkynyl and -CO₂R⁴ wherein

R³ is hydrogen or C₁₋₄alkyl,


R⁴ is hydrogen or C₁₋₄alkyl,

R^{4A} and R^{4B} are each independently selected from hydrogen, C₁₋₄alkyl, -C₁₋₄alkylC₁₋₄alkoxy, and COR⁴, or

R^{4A} and R^{4B}, together with the nitrogen atom to which they are attached, join together to form a cyclic amino group, wherein the cyclic amino group is optionally substituted with oxo;

Ar² is a ring system selected from Groups (i), and (ii), wherein:

Group (i) is a 5-membered heteroaryl ring system selected from any one of (IIa) to (IIm):



wherein X^6 , X^7 , X^8 , and X^9 are each independently selected from O, S, and NH, and

R^5 is one or more optional substituents each independently selected from halogen, cyano, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, $-C_{1-4}$ alkyl C_{1-4} alkoxy, $-CO_2R^6$, and $-L-Q$ wherein:

L is a linker group selected from a direct bond, C_{1-3} alkylene and $-CO-$; and

Q is a group selected from $NR^{5A}R^{5B}$, C_3 cycloalkyl and 4-7 membered heterocyclyl, wherein the 4-7 membered heterocyclyl ring is optionally substituted with one or more substituents selected from halogen, cyano, C_{1-4} alkyl, C_{1-4} alkoxy and CO_2R^6 ;

R^{5A} and R^{5B} are each independently selected from hydrogen, C_{1-4} alkyl, C_{3-7} cycloalkyl, COR^7 , $-C_{1-4}$ alkyl- NR^8R^9 , $-C_{1-4}$ alkyl C_{1-4} alkoxy, phenyl and 5 or 6-membered heteroaryl wherein the phenyl or 5 or 6-membered heteroaryl rings are optionally substituted with one or more substituents selected from halogen and C_{1-4} alkyl; or


R^{5A} and R^{5B} , together with the nitrogen atom to which they are attached, join together to form a cyclic amino group, which cyclic amino group is optionally substituted with one or more groups selected from halogen, C_{1-4} alkyl, C_{1-4} alkoxy, cyano, and CO_2R^6 ,

R^6 is hydrogen, C_{1-4} alkyl or an alkali metal;

R^7 is C_{1-4} alkyl

R^8 and R^9 are each independently selected from hydrogen and C_{1-4} alkyl;

Group (ii) is a 5,6-fused bicyclic heteroaryl ring system having the formula (III):




wherein Y^2 is selected from O and NR^{5C} ;

R^{5C} is hydrogen or C_{1-4} alkyl,

X^{10} , X^{11} , X^{12} , and X^{13} are each independently selected from N and CH;

R^{10} is one or more optional substituents each independently selected from halogen, cyano, C_{1-4} alkyl, halo C_{1-4} alkyl, C_{1-4} alkoxy, and $-CO_2R^4$;

PROVIDED THAT the compound of formula (I) is other than:



and preferably wherein the compound of formula (I) is for use in the manufacture of a medicament for the treatment of infection with, or disease caused by a bacterium selected from *Enterococcus faecalis*, *Enterococcus faecium* and the *Neisseria* genus; more preferably for use in the treatment of infection with, or disease caused by a bacterium selected from the *Neisseria* genus; and most preferably for use in the manufacture of a medicament for the treatment of infection with, or disease caused by the bacterium *Neisseria gonorrhoeae*.

19. A combination treatment comprising: a compound according to any one of claims 1 to 12 and a therapeutic agent having anti-chlamydia activity, preferably the therapeutic

agent having anti-chlamydia-activity is selected from: azithromycin, erythromycin, doxycycline, levofloxacin, ofloxacin, and amoxicillin.